Durable remission with salvage decitabine and donor lymphocyte infusion (DLI) for relapsed early T-cell precursor ALL.

El Chaer, F; Holtzman, N; Binder, E; Porter, N C; Singh, Z N; Koka, M; Rapoport, A P; Emadi, A

El Chaer, F; Holtzman, N; Binder, E; Porter, N C; Singh, Z N; Koka, M; Rapoport, A P; Emadi, A.

Affiliation

El Chaer F; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Holtzman N; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Binder E; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Porter NC; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Singh ZN; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA.
Koka M; Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA.
Rapoport AP; Department of Neurology, University of Maryland School of Medicine, Baltimore, MD, USA.
Emadi A; Department of Pathology, University of Maryland School of Medicine, Baltimore, MD, USA.

Bone Marrow Transplant ; 52(11): 1583-1584, 2017 11.

Article de En | MEDLINE | ID: mdl-28892087

Sujet(s)

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Azacitidine / Thérapie de rattrapage / Transfusion de lymphocytes / Leucémie-lymphome lymphoblastique à précurseurs T Limites: Aged / Humans / Male Langue: En Journal: Bone Marrow Transplant Sujet du journal: TRANSPLANTE Année: 2017 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: Royaume-Uni

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google